Table of Contents
<< Previous Issue | Sept 2022 (Vol: 2022, Issue: 9) | Next Issue >> |
- Section: Licensing
-
Zealand Pharma Signs Licensing Agreement with Novo Nordisk for Zegalogue®
-
GSK Pays US$66 M Upfront for Spero’s Late-Stage Antibiotic
- Section: Mergers & Acquisitions
-
Roche Acquires Good Therapeutics for US$250 M Upfront
-
Novo Nordisk to Acquire Forma Therapeutics for US$1.1 B
-
Genfit Buys Versantis to Rebuild its Liver Disease Portfolio